Study S002773

A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07134335
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 180
Start: 2025-09-01
Primary completion: 2030-07-11
Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Conditions: Obesity &Amp; Overweight; Chronic Kidney Disease
Interventions: DRUG:UBT251
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

log-transformed urinary albumin:creatinine ratio（UACR） [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.